Injectable Drug Delivery Market is expected to reach $43.3 Billion by 2017

Injectable drug delivery via liposomes is a delivery system for injectable drugs in biomedical field. A liposome is an artificially-prepared spherical vesicle composed of a lipid bi-layer which can be used as a delivery system for administration of nutrients and pharmaceutical drugs. Liposomes are microscopic vesicles composed of one or more lipid membranes surrounding discrete aqueous compartments. Liposomes can encapsulate water-soluble drugs in their aqueous spaces and lipid-soluble drugs within the membrane itself. 

There are four ways by which liposomes release their contents by interacting with cells:

1.       adsorption,

2.       endocytosis,

3.       lipid exchange,

4.       or fusion.

The four major factors which effects liposomes’ distribution and in vivo behavior are mentioned below:

1.     Liposomes tend to leak if cholesterol is not included in the vesicle membrane.

2.     Small liposomes are cleared more slowly than large liposomes.

3.     The half-life of a liposome increases as the lipid dose increases.

4.     Charged liposomal systems are cleared more rapidly than uncharged systems. 

                                   Source: http://www.nanopharmaceuticals.org/

According to new market research report, the global injectable drug delivery market is expected to reach $43.3 billion by 2017 at a CAGR of 14.0% from 2012 to 2017. The report categorizes the global market by Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors], Formulations [Liposomes, Microspheres, & Nanoparticles] & Geography. It provides the complete analysis of the global injectable drug delivery market and its forecasts up to 2017.

According to the report the past decade has seen a significant shift in terms of the types of approved injectible drugs delivery systems and the type of diseases they target. This dramatic shift has boosted the liposomes market a marked increase in the level of drug & device integration which has fostered several layers of the healthcare sector to change. The report examines the total liposomes market by key therapeutic, product, market and regulatory factors for injectable drugs, providing essential insight and forecast into the implications of this evolving landscape of injectible drug delivery market.

The liposomes market is also segmented on the basis of its therapeutic applications like auto immune diseases, hormonal imbalances, oncology, orphan diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, and Wilson’s disease) and others like pain management and allergies. Hormonal disorders commanded the largest share and it is expected to grow at a CAGR of 13.9% to reach $21.6 billion by 2017. The major geographic markets covered in this report are North America, Europe, Asia-Pacific, and RoW. North America dominates the liposomes market, followed by Europe. However, Asian and Latin American countries are the fastest growing markets due to growing number of cancer and diabetes incidences, and improving patient compliance.

The report can be referred here:
http://www.prweb.com/releases/injectable-drug-delivery/market/prweb11510958.htm